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BACKGROUND: Progressive tumour growth is dependent on the development of a functional tumour vasculature and highly regulated
by growth factors and cytokines. Nitric oxide (NO) is a free radical, produced both by tumour and host cells, and functions as a
signalling molecule downstream of several angiogenic factors. Both pro- and antitumourigenic properties have been attributed to NO.
METHODS: The expression of the inducible isoform of NO synthase (iNOS) was knocked down in the C6 glioma cell line using
constitutive expression of antisense RNA, and the effect of tumour-derived NO on tumour progression and angiogenesis was
investigated.
RESULTS: Tumours in which iNOS expression was decreased displayed significantly reduced growth rates compared with tumours
derived from parental C6 cells. Quantitative non-invasive magnetic resonance imaging and fluorescence microscopy of tumour
uptake of Hoechst 33342, and haematoxylin and eosin staining, revealed significantly impaired vascular development and function in
antisense iNOS tumours compared with control in vivo, primarily associated with the more necrotic tumour core. Decreased iNOS
expression had no effect on tumour VEGF expression.
CONCLUSION: Nitric oxide derived from tumour iNOS is an important modulator of tumour progression and angiogenesis in C6
gliomas and further supports the therapeutic strategy of inhibiting iNOS for the treatment of cancer.
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Progressive tumour growth and survival is dependent on
angiogenesis, the development of a functional blood supply to
provide nutrients and remove waste products. Without the
concomitant growth of new blood vessels or cooption of existing
capillary networks, tumours cannot expand beyond a minimal size
or metastasise to distant sites (Folkman, 1995; Carmeliet and Jain,
2000). Angiogenesis is stimulated by the release of specific growth
factors from tumour, endothelial, accessory (stromal) host cells
and/or associated macrophages, and production of these factors is
upregulated by conditions associated with the classical hallmarks
of the tumour microenvironment (e.g., elevated interstitial fluid
pressure, hypoxia), all of which are consistent with a compromised
blood supply (Yancopoulos et al, 2000). Although extensively
studied, the molecular mechanisms that regulate tumour blood
vessel development and function remain elusive, and are a reason
for the apparent paucity of potent antiangiogenic therapies.
A plethora of angiogenic stimuli induce the production of nitric
oxide (NO), an important inter- and intracellular signalling
molecule synthesised from arginine by NO synthases (NOS). Of
the three isoforms of NOS, specifically inducible (iNOS),
endothelial (eNOS) and neuronal, iNOS produces the greatest
amounts of NO and is associated with a number of pathologies
(Moncada et al, 1991). Although their precise role is still unclear,
both iNOS and eNOS activities have been implicated in tumour
progression and angiogenesis, and their effectiveness appears to be
dependent on their activity and distribution, the concentration and
duration of exposure to NO, and the intrinsic sensitivity of cells to
NO (Fukumura et al, 2006). For example, transfection of K-1735
murine melanoma with iNOS decreased the rate of tumour growth
by inducing apoptosis (Xie et al, 1995). In contrast, overexpression
of iNOS in DLD-1 colon carcinoma cells results in more aggressive
and better vascularised tumours compared with wild type (Jenkins
et al, 1995; Cullis et al, 2006). In addition, delivery of iNOS
through gene transfer has been shown to both radiosensitise
tumours and have direct cytotoxicity in vivo (Worthington et al,
2004). The results obtained from clinical studies have been more
equivocal, revealing positive correlations between iNOS expression
and grade in a wide range of human cancers, including brain
tumours (Cobbs et al, 1995; Ellie et al, 1995; Ambs et al, 1998).
More importantly, increased expression of iNOS in both human
breast cancer and melanoma has recently been shown to be
associated with poor outcome/survival (Loibl et al, 2005;
Ekmekcioglu et al, 2006).
The effect of altered NO levels on tumour growth and
angiogenesis has also been exploited through pharmacological
manipulation with either NO donors or NOS inhibitors. Treat-
ment of mice bearing mammary and squamous carcinomas with
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NG-nitro-L-arginine methyl ester, a universal NOS inhibitor, as well
as specific inhibition of iNOS by either 1400W or L-nil, reduced
subcutaneous tumour growth and vessel development (Thomsen
et al, 1997; Jadeski and Lala, 1999; Sikora et al, 2010). Although
these observations indicate a tumour-promoting role for NO, the
effect of NOS inhibition could not be ascribed specifically to
tumour-derived NO, as NOS inhibition can affect other aspects of
host physiology. These systemic effects were highlighted during
studies in which low concentrations of NO donors inhibited
angiogenesis and tumour growth, whereas higher doses of NO
donors caused a reduced response because of interference with
host physiology (Pipili-Synetos et al, 1995). A single dose of
the NOS inhibitor NG-nitro-L-arginine (L-NNA) was shown to
induce an acute and sustained reduction in human tumour blood
volume, providing clinical evidence that inhibition of NOS has
tumour antivascular effects (Ng et al, 2007). The importance of
host-derived NO for tumour growth has also been shown
genetically in studies using iNOS knockout mice, wherein tumour
growth and vascularisation were decreased (Konopka et al, 2001;
Wang et al, 2001). However, tumour cells are a major source of NO
production that can affect angiogenesis and modulate tumour
progression. Therefore, careful examination of the role of tumour-
derived NO is important in understanding tumour physiology and
in the design of effective therapeutic interventions.
In this study we have investigated the role of tumour cell-
derived iNOS on growth and angiogenesis in a model of
glioma, which clinically represents one of the most vascularised
human cancers (Wesseling et al, 1997). The expression of iNOS
in C6 glioma cells was reduced using an endogenous anti-
sense approach, and the growth potential of these antisense-iNOS
cells was examined in vivo. Furthermore, the functional blood
supply of tumours derived from these manipulated cell lines
was investigated in vivo using non-invasive magnetic reso-
nance imaging (MRI), and complemented with fluorescence
microscopy.
MATERIALS AND METHODS
Cell culture and transfection
The rat glioma C6 cell line (European Collection of Cell Cultures,
Salisbury, UK) was maintained in Nutrient Ham’s F-10 (Sigma,
Dorset, UK) culture medium containing 2mM L-glutamine,
100Uml1 penicillin, 0.1mgml1 streptomycin and 10% (v/v)
fetal calf serum. The antisense iNOS stable-transfected cell lines
(subsequently termed AS lines) were produced by transfection
with the pciNOS500 plasmid using the poly L-ornithine method
(Kostourou et al, 2002) and selected by culture in hygromycin
(500mgml1). For the generation of the pciNOS500 plasmid, the
fragment of murine iNOS (5707–6247 bp), previously shown to be
an effective antisense target (Cartwright et al, 2000), was extracted
from the original clone in pSG5 vector using BamHI restriction
enzyme and subcloned into the BamHI site in pcDNA 3.1 (þ )/
hygro vector (Invitrogen, Paisley, UK).
Western blot analysis
Cell extracts were generated from stably transfected antisense cell
lines (AS7, AS9 and AS12) and parental C6 cells with cytokine
stimulation (10 ngml1 TNF-a, 100Uml1 IFN-g, 5 mgml1 LPS
for 24 h), and from tumour homogenates of AS7 and C6 tumours
(Kostourou et al, 2002). Protein concentration was measured by
the Bradford method according to the manufacturer’s instructions
(Sigma, Poole, Dorset, UK). An equal amount of protein was
analysed by SDS–PAGE and the iNOS protein was detected using
a polyclonal anti-mouse iNOS antibody (M-19, Santa Cruz,
Heidelberg, Germany). Equal protein loading was verified on
tumour homogenate blots using a monoclonal anti-b-actin anti-
body (AC-15, Abcam, Cambridge, UK).
Nitrite production
C6, AS7 and AS12 cells were stimulated with 10 ngml1 of TNF-a,
100Uml1 of IFN-g and 5 mgml1 of LPS for up to 72 h and the
nitrite production was determined using the Greiss reaction as
previously described (Kostourou et al, 2002).
In vitro growth
The growth of C6 and AS7 cells under normal culture conditions
or after cytokine stimulation (5mgml1 LPS, 100Uml1 IFN-g and
10 ngml1 TNF-a) was determined using a dye-binding assay, in
which the concentration of the eluted dye is linearly correlated to
the cell number (Winterbourne, 1993). AS7 and C6 cells were
seeded at a density of 1000 cells per well in 24-well plates. Fresh
medium alone or with addition of cytokines was added every
2 days. Cell number was determined in duplicate wells at daily
intervals for a period of 6 days. The cells were fixed in 300 ml
fixation solution (10% (v/v) formalin in 5% (w/v) polyvinylpyrro-
lidone) for 5min. The wells were then washed three times with
water and air-dried. The cells were stained with 600 ml of
filtered 0.04% (w/v) Coomassie Blue R250 (Sigma) in 25%
(v/v) ethanol/12% (v/v) acetic acid for 1 h, washed three times
with 600ml of 10% (v/v) ethanol/5% (v/v) acetic acid and allowed
to dry. Cell growth was quantified by eluting the stain in 600 ml
filtered solution of 1M potassium acetate in 70% ethanol for 1 h
and measuring absorbance at 620 nm using a Titertek Multiscan
microtitre plate reader (Titertek, McLean, VA, USA).
Animals and tumours
All procedures were performed in accordance with the local ethical
review panel, the UK Home Office Scientific Procedures Act 1986
and the UKCCCR guidelines (Workman et al, 2010). Female
(7–8 weeks old) MF1/nu mice were injected subcutaneously in
the flanks with AS7, AS12 or C6 cells in 0.1ml PBS. Tumour
growth was measured at daily intervals after briefly anaesthetising
the mice with fluothane in 2% N2O, 5% O2. The dimensions of
the tumour under the skin were measured using calipers and
tumour volume was calculated using the following formula:
tumour volume¼ p/6  (lengthwidth depth).
Magnetic resonance imaging
Fractional tumour blood volume was evaluated in vivo using
susceptibility contrast MRI (Robinson et al, 2003). Intravascular
contrast agents such as ultrasmall superparamagnetic iron
oxide (USPIO) particles create magnetic susceptibility variations
inducing an increase in the MRI transverse relaxation rate
R2* (s
1) of water in the surrounding tissue. Changes in tissue
R2* caused by USPIO particles are dependent on blood volume;
hence, an estimate can be made by measuring the absolute changes
in R2* following administration of USPIO particles. As USPIO
particles probe for blood vessels that are functional at the time of
injection, and not necrotic areas or vessels with static blood flow,
a USPIO-induced measurement of DR2* can provide a valuable
non-invasive imaging biomarker associated with tumour angio-
genesis (Kostourou et al, 2003; Robinson et al, 2008). A multi-
gradient echo (MGRE) MRI sequence was used to quantify R2*
of size-matched (B0.8 cm3) AS7 and C6 tumours before and after
the intravenous administration of 2.5mg Fe kg1 of the USPIO
contrast agent feruglose (GE Healthcare, Oslo, Norway) through a
lateral tail vein. Apparent R2* maps were calculated on a voxel-by-
voxel basis from the MGRE image data sets, and the average
apparent R2* relaxation rates were calculated for each tumour for a
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region of interest encompassing the whole tumour image but
excluding any surrounding skin and muscle. Having determined
the DR2* values (R2* post-USPIOR2* pre-USPIO), estimates of the
fractional tumour blood volume (x, %) were then derived as
previously described (Robinson et al, 2003, 2008).
Immunohistochemistry and fluorescence microscopy
Mice bearing size-matched AS7 and C6 tumours were injected
intravenously with 15mg kg1 of the perfusion marker Hoechst
33342 (Sigma) 1min before excision of the tumour (Kostourou
et al, 2003; Cullis et al, 2006). Three acetone-fixed cryosections
(8–10 mm) of each C6 and AS7 tumours were then visualised
for Hoechst 33342 uptake by fluorescence microscopy using
appropriate filters (355 nm excitation, 465 nm emission). To assess
vessel density, additional frozen tumour sections were first
rehydrated with PBS, and then incubated with 2% BSA/5% goat
serum in PBS for 30min at room temperature. After washing with
PBS, sections were incubated with rat anti-mouse PECAM
monoclonal antibody (1 : 500 dilution, BD Pharmingen, Basing-
stoke, UK) for 1 h at room temperature, and then washed
extensively in PBS/0.1% Tween-20. Biotinylated anti-rat immuno-
globulins (1 : 100, Vector Laboratories, Burlingame, CA, USA) were
then applied onto the sections and incubated for 1 h at room
temperature. Following extensive washing in PBS/0.1% Tween-20,
sections were incubated with fluorescein streptavidin (1 : 100) in
the dark for 30min, washed with PBS/0.1% Tween-20 and
mounted using Vectashield mounting medium (Vector Labora-
tories). Endothelial structures were subsequently visualised by
fluorescence microscopy at 450–490 nm. Whole tumour sections
were scanned using a computer-controlled motorised scanning
stage (Marzhauser, Wetzlar-Steindorf, Germany) driven by
Stage-Pro (Media Cybernetics, Wokingham, UK) on an IX70
fluorescence microscope (Olympus Optical, London, UK). Digital
images from both AS7 and C6 tumour sections were acquired
using the same exposure time and composite images were
synthesised. The digital images were analysed using analySIS
software (Soft Imaging System, Munster, Germany). Fluorescent
particles were detected above a constant threshold for all the
composite images, and the area of the tumour section with
fluorescein and Hoechst 33342 fluorescence was determined and
expressed as a percentage of the whole tumour section.
Additional formalin-fixed tumour sections were cut and stained
with haematoxylin and eosin to assess tissue viability of AS7, AS12
and C6 tumours.
Production and detection of VEGF
Culture medium was collected from confluent six-well plates
containing C6 and AS7 cells under normal culture conditions or
after cytokine stimulation, and analysed for VEGF165 expression
using a murine VEGF ELISA kit (R&D Systems, Abingdon, UK).
In addition, tumours were excised, weighed, cut into small pieces
and maintained in culture medium for 4 days, following which the
secretion of VEGF165 by the tumour explants into the culture
medium was also determined by ELISA (Kostourou et al, 2002).
RESULTS
Inhibition of iNOS expression in C6 glioma cells
A number of hygromycin-resistant C6 cell lines were isolated
following transfection with plasmid pcDNA 3.1 expressing a 500
base fragment of murine iNOS cDNA in an antisense orientation.
The efficacy of this fragment to inhibit the expression of iNOS in
these lines was determined by western blot analysis. Under basal
conditions, the expression of iNOS by C6 cells was undetectable.
On stimulation with TNFa, IFNg and LPS for 24 h, iNOS expression
was increased (Figure 1A). In cells expressing antisense iNOS,
there was variable but significant inhibition of iNOS expression.
The most significant reduction in iNOS expression was exhi-
bited by clones AS7 and AS12, and these lines were chosen for
further investigations. The decrease in iNOS protein expression
was corroborated by the reduced NO production by AS7 and
AS12 cells, as determined by measuring the accumulation of
nitrite following stimulation with TNFa, IFNg and LPS for 24 h.
The AS7 and AS12 clones displayed significant inhibition of
NO production 24 h after cytokine stimulation (76 and 63%,
respectively), compared with parental C6 cells, and this level of
inhibition of iNOS activity remained similar at the later time point
of 48 h (Figure 1B). The reduction in iNOS expression did not
alter the in vitro growth properties of C6 cells. The basal- or
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Figure 1 Characterisation of antisense iNOS cell lines in vitro. (A) Cytokine-induced (10 ngml1 TNF-a, 100Uml1 IFN-g, 5 mgml1 LPS for 24 h) iNOS
expression from parental C6 and antisense iNOS clones AS7, AS9 and AS12 determined by western blot. (B) Nitrite production in parental C6 and
antisense iNOS clones AS7 and AS12 determined 24 and 48 h after cytokine stimulation. Results are mean±1 s.e.m. of triplicate of three separate
experiments, ***Po0.001, Student’s t-test. (C) In vitro growth rate of parental C6 and AS7 cells under normal culture conditions or after cytokine
stimulation (10 ngml1 TNF-a, 100Uml1 IFN-g and 5mgml1 LPS). Results are mean±1 s.e.m. of triplicate of three separate experiments. Note that
decreased iNOS expression does not affect in vitro tumour cell growth and survival.
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cytokine-stimulated survival of AS7 cells was no different from
that of parental C6 cells (Figure 1C).
Effect of inhibiting iNOS expression on tumour growth
in vivo
In contrast to their growth in vitro, when AS7 or AS12 cells were
inoculated into the flanks of nude mice, the tumour growth rate
in vivo was significantly slower (AS7 doubling time of B5 days)
than that of C6 tumours (doubling time of B4 days, Figure 2A).
Tumours derived from AS12 cells exhibited a growth rate similar
to that of AS7 tumours. AS7 tumours became palpable and
measurable 13 days post inoculation of cells compared with C6
tumours, which could be measured 10 days post inoculation. After
20 days of growth, the mean tumour size of AS7 tumours was half
that of C6 tumours. Inhibition of iNOS expression in AS7 tumours
was confirmed by western blot analysis of tumour homogenates
(Figure 2B).
Effect of inhibiting iNOS expression on tumour vascular
development
Susceptibility contrast-enhanced MRI using the USPIO contrast
agent feruglose was used to interrogate any differences in
magnitude and distribution of fractional blood volume between
size-matched C6 and AS7 tumours. Calculated DR2* maps of C6
and AS7 tumours are shown in Figure 3A. Visual inspection of the
tumour DR2* maps consistently revealed that feruglose uptake was
mainly restricted to the tumour periphery of AS7 tumours,
compared with the more heterogeneous DR2* maps of C6 tumours.
Administration of feruglose significantly increased R2* of the C6
tumours only (Figure 3B). The mean fractional tumour blood
volume (x) derived from these data was 1.4±0.1% and 0.9±0.2%
for C6 and AS7 tumours, respectively.
Tumour perfusion was also assessed by quantifying the uptake
of the fluorescent perfusion marker Hoechst 33342. This is a
nuclear dye that, on injection, stains endothelial cells and cells
immediately adjacent to tumour blood vessels. The time from
injection to euthanisation was limited to 1min to prevent
excessive diffusion of the dye beyond the cells lining perfused
blood vessels within the tumour. Thus, Hoechst 33342 uptake
reports only on functionally perfused vessels, and also provides
validation of the MRI data. Composite images of Hoechst
33342 uptake showed that, as with MRI data, AS7 tumours had
fewer perfused areas compared with C6 tumours, and that these
regions were restricted mainly to the tumour periphery
(Figure 4A). The perfused vessels were quantified using image
analysis techniques and the mean perfused area of AS7 tumours
was significantly lower compared with that of C6 tumours
(Figure 4B). In comparison, the pan-endothelial marker PECAM
was more homogeneously and extensively distributed across both
C6 and AS7 tumours, with no significant difference in vessel
density between the two tumour types (Figure 4A and C).
Composite images of whole haematoxylin and eosin-stained
sections of C6, AS7 and AS12 tumours are shown in Figure 4C.
Essentially, the darker stain is indicative of more viable tissue.
Histological examination of the sections showed that AS7 and
AS12 tumours exhibited a high degree of tissue heterogeneity,
central necrosis and reduction of viable tissue, consistent with
insufficient perfusion, compared with the more homogeneous and
viable parental C6 gliomas.
Decreased AS7 tumour perfusion is not mediated by
decreased VEGF expression
Nitric oxide has also been shown to both stimulate and inhibit
VEGF expression in a cell-dependent manner and is a potent
modulator of vascular development and tumour progression (Chin
et al, 1997; Tsurumi et al, 1997; Liu et al, 1998; Yancopoulos et al,
2000). In vitro studies of AS7 and C6 cells showed that both cell
lines produced similar levels of VEGF165. Induction of iNOS with
cytokines for 24 h resulted in a significant 1.5-fold upregulation of
VEGF165 in both AS7 and C6 cell lines (Figure 5A). In addition, the
concentration of VEGF165 in the medium of tumour explants
exhibited no significant differences between AS7 and C6 tumours,
as determined by ELISA (Figure 5B).
DISCUSSION
The effect of NO, and in particular tumour cell-derived NO, on
tumour growth and angiogenesis is still unclear. Numerous
preclinical studies have implicated NO in both tumour growth
and angiogenesis in vivo with controversial conclusions (Jenkins
et al, 1995; Thomsen et al, 1997; Ambs et al, 1998; Jadeski and Lala,
1999; Camp et al, 2006; Cullis et al, 2006; Sikora et al, 2010). The
majority of these studies used pharmacological manipulation of
NO with either NO donors or inhibitors. There are, however,
several disadvantages with this approach, including the lack of
NOS isoform selectivity of existing inhibitors, and their systemic
effects on host physiology. In addition, NO donors can rapidly
generate high levels of NO, together with other cytotoxic molecules
such as cyanide, reactive nitrogen intermediates, peroxynitrite and
superoxide, making it impossible to dissect the role of NO from the
cytotoxicity caused by other reactive species (Borutaite et al, 2000).
In vivo, cells are more likely to experience lower concentrations
of NO over prolonged time periods.
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Figure 2 Effect of antisense iNOS on tumour growth in vivo.
(A) Normalised growth rates of tumours derived from parental C6
(n¼ 6), AS7 (2 106, n¼ 5) or AS12 (1 106, n¼ 5) cells, grown
subcutaneously in the flanks of female nude mice. Data points are
mean±1 s.e.m. Note the significantly slower growth rate of AS7 and AS12
tumours. (B) Western blot of AS7 and C6 tumour homogenates, showing
reduced expression of iNOS in the AS7 tumours.
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In this study, an alternative approach was taken that aimed to
overcome some of these shortcomings. Instead of overexpressing
the iNOS isoform, which could result in non-physiological,
extremely high levels of NO, the role of iNOS on tumour growth
and angiogenesis was studied by more subtly decreasing endo-
genous iNOS expression using antisense technology. Rat C6 glioma
cells, which express iNOS, were used, as tumours derived from
them represent a well-established model of human glioblastoma
(Simmons and Murphy, 1992; Barth, 1998). Furthermore, positive
correlations of malignancy with iNOS expression have been shown
in human brain tumours (Cobbs et al, 1995; Ellie et al, 1995),
which typically present as highly vascularised tumours in the clinic
(Wesseling et al, 1997). Although the growth rate of these cells
in vitro was unaltered, tumours derived from the iNOS-antisense-
transfected C6 cell lines displayed significantly reduced growth
in vivo compared with tumours derived from wild-type C6 cells.
Compared with control, cytokine-stimulated AS7 and AS12 clones
exhibited a clear reduction in iNOS expression and nitrite
production in vitro, and reduced iNOS expression was found in
AS7 tumours.
Together, these data emphasise the importance of tumour
cell-derived iNOS in the progression of C6 gliomas. The absence of
a substantial difference in iNOS expression in vivo presumably
reflects contributions of iNOS from accessory cells, especially
macrophages, within solid tumours. Propagation and interrogation
of tumours from these clones in iNOS knockout mice should
provide an even more unambiguous assessment of the contri-
bution of tumour cell-derived iNOS. Using a similar antisense
approach, Yamaguchi et al (2002) reported that decreased iNOS
expression resulted in reduced glioma formation in an orthotopic
rat C6 striatal implantation model. However, the mechanism for
the failure of tumour growth was not clarified. It was speculated
that decreased expression of iNOS in tumour cells may render
them more sensitive to the host immune response. Here we
provide evidence for an alternative mechanism by which tumour-
derived NO affects tumour growth. Determination of fractional
tumour blood volume by non-invasive susceptibility contrast MRI,
and histologically qualified with fluorescence microscopy of
Hoechst 334342 uptake, revealed that decreased tumour growth
is a result of a dysfunctional vascular network that did not support
effective tumour perfusion, particularly within the tumour core.
To accommodate sustained tumour growth, the vasculature has
to undergo constant remodelling. As a part of this process and as a
result of the elevated interstitial fluid pressure (IFP) associated
with tumours, and because of local imbalances of angiogenic
factors and or intermittent blood flow, some vessels within the
tumour may collapse and cease to function. Although these vessels
will stain positive for endothelium and contribute to the vessel
density measurements, they will not necessarily contribute to
tumour growth (Eberhard et al, 2000). We therefore used
susceptibility contrast MRI in vivo and fluorescence microscopy
of Hoechst 33342 uptake to assess the degree and distribution of
any functional differences in the perfusion of vessels derived from
the two cell types in vivo, and showed that inhibition of iNOS
resulted in reduced tumour perfusion primarily restricted to the
tumour periphery. Nitric oxide is a potent mediator of tumour
vascular tone (Fukumura et al, 2006). Sustained functional tumour
perfusion, assessed by Hoechst 33342 uptake, within the core of
DLD-1 colon carcinomas derived from cells constitutively over-
expressing iNOS, has been reported, and it was hypothesised that
the increased concentration of NO may abrogate any IFP-induced
vascular collapse (Cullis et al, 2006). Similarly, inhibition of iNOS
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Figure 3 Effect of antisense iNOS on tumour blood volume assessed by MRI. (A) Calculated DR2* maps of C6 and AS7 tumours. Note the dark core
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may facilitate IFP-induced vascular collapse, resulting in the
absence of functional tumour perfusion within the AS7 tumours
reported herein.
Several factors have been implicated in tumour development,
one of the most prominent being VEGF, which induces sprouting
angiogenesis, increases blood vessel permeability and maintains
tumour vessel integrity (Yancopoulos et al, 2000). The expression
of VEGF has been shown to be a survival factor for blood vessels in
C6 gliomas (Benjamin and Keshet, 1997). Nitric oxide can induce
VEGF expression and mediate the angiogenic effects of VEGF
(Ambs et al, 1999). We therefore hypothesised that the reduced
growth and vessel perfusion of AS7 tumours would be associated
with decreased VEGF expression. However, our in vitro and
ex vivo analyses of VEGF expression and production in tumour
cells and explants revealed no significant differences between AS7
and C6 gliomas, coupled with no difference in vessel density as
revealed by PECAM immunohistochemistry. Endothelial NOS has
been shown to have a predominant role in VEGF-induced
angiogenesis (Fukumura et al, 2001). This, coupled with the data
herein, suggests that NO produced from iNOS activity is important
in the maintenance of tumour blood vessel tone and function, and
further highlights the apparent differing roles of the NOS isotypes,
and their tissue/cell type of origin, on tumour angiogenesis in vivo.
In conclusion, we have shown (i) by using an antisense
approach that NO derived from tumour cell expression of iNOS
is a key modulator of tumour growth and angiogenesis, and (ii) the
ability of susceptibility contrast MRI to non-invasively assess
the effects of tumour-derived iNOS on vascular development and
function in C6 gliomas in vivo. Inhibition of NOS following
treatment with L-NNA has been shown to have antivascular activity
in human tumours (Ng et al, 2007). Together, these data further
support the concept of inhibiting iNOS as a therapeutic strategy for
the treatment of cancer.
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